See more : Libord Securities Limited (LIBORD.BO) Income Statement Analysis – Financial Results
Complete financial analysis of PAO Group, Inc. (PAOG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PAO Group, Inc., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- Lynas Rare Earths Limited (LYSCF) Income Statement Analysis – Financial Results
- Yakult Honsha Co.,Ltd. (YKLTF) Income Statement Analysis – Financial Results
- Atour Lifestyle Holdings Limited (ATAT) Income Statement Analysis – Financial Results
- Mangata Holding S.A. (MGT.WA) Income Statement Analysis – Financial Results
- Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332.SS) Income Statement Analysis – Financial Results
PAO Group, Inc. (PAOG)
About PAO Group, Inc.
PAO Group, Inc. focuses on alternative patient care treatments. The company, through its subsidiaries, engages in the development, sale, and distribution of premium medical cannabis products for treatment of chronic and terminal patients. The company is headquartered in Sandusky, Ohio.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 287.82K |
| Cost of Revenue | 0.00 | 2.74K | 1.80K | 0.00 | 0.00 | 250.12K |
| Gross Profit | 0.00 | -2.74K | -1.80K | 0.00 | 0.00 | 37.70K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 13.10% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 45.42K | 185.81K | 340.32K | 14.31K | 72.86K | 244.43K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -4.13K | 0.00 |
| Operating Expenses | 45.42K | 185.81K | 340.32K | 14.31K | 76.99K | 244.43K |
| Cost & Expenses | 45.42K | 188.55K | 342.12K | 14.31K | 76.98K | 494.55K |
| Interest Income | 0.00 | 0.00 | 97.53K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 57.46K | 62.61K | 55.72K | 35.89K | 58.53K | 103.76K |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K | 171.86K | 161.14K |
| EBITDA | 292.96K | -188.55K | -244.59K | -14.31K | 1.20M | -206.73K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -71.83% |
| Operating Income | -45.42K | -188.55K | -342.12K | -14.31K | -76.99K | -206.73K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -71.83% |
| Total Other Income/Expenses | 280.93K | -62.61K | 41.81K | -37.24K | 1.22M | -103.76K |
| Income Before Tax | 235.51K | -251.16K | -300.30K | -51.55K | 1.14M | -310.49K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -107.88% |
| Income Tax Expense | -167.90K | -228.49K | -236.56K | -206.30K | -171.86K | -161.14K |
| Net Income | 235.51K | -251.16K | -300.30K | -51.55K | 1.14M | -310.49K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -107.88% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 1.91B | 1.91B | 1.91B | 1.40B | 914.18M | 815.18M |
| Weighted Avg Shares Out (Dil) | 1.91B | 1.91B | 1.91B | 1.40B | 914.18M | 815.18M |
PAOG CBD Pharmaceutical Respiratory Treatment Research Garners New Interest
Sandusky, OH, Oct. 13, 2021 — McapMediaWire — PAO Group, Inc. (OTC Pink: PAOG) today announced encountering a flurry of outside interest of late into the company's CBD pharmaceutical respiratory treatment research. Last year, the company acquired intellectual...
PAOG Announces Imminent Launch Of First CBD Nutraceutical Product Line - Q4 Sales Projected With Rapid Revenue Growth Anticipated To Follow
SANDUSKY, Ohio, Oct. 12, 2021 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today announced the company expects to realize its first CBD nutraceutical product sales beginning imminently in Q4, 2021. The company confirms shipping its first CBD nutraceutical product to...
PAOG Set To Realize First CBD Nutraceutical Sales In Q4 With Rapid Revenue Growth Expected To Follow
Sandusky, OH, Oct. 11, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today announced the company expects to realize its first CBD nutraceutical product sales beginning imminently in Q4, 2021.
PAOG Ships First CBD Nutraceutical Product To Distributor Entering $16 Billion Market
Sandusky, OH, Oct. 07, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today announced shipping its first CBD nutraceutical product to its distribution partner.
PAOG To Build On CBD Business Through Acquisition
SANDUSKY, OH, Oct. 5, 2021 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today announced the company is actively exploring merger and acquisition opportunities targeted at expanding the company's product line and accelerating revenue growth. The company recently announced initiating production...
PAOG Targets Expansion And Accelerated Revenue Growth Through M&A To Complement Existing CBD Business
Sandusky, OH , Oct. 04, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC PINK: PAOG) today announced the company is actively exploring merger and acquisition opportunities targeted at expanding the company's product line and accelerating revenue growth.
PAOG Targets Expansion And Accelerated Revenue Growth Through M&A To Complement Existing CBD Business
Sandusky, OH, Oct. 04, 2021 — McapMediaWire — PAO Group, Inc. (OTC PINK: PAOG) today announced the company is actively exploring merger and acquisition opportunities targeted at expanding the company's product line and accelerating revenue growth. The company recently announced...
PAOG On Track To Begin Generating Revenue This Year From CBD Nutraceutical Sales
Sandusky, OH , Sept. 30, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today announced the company has initiated production on its first line of CBD nutraceuticals and is on track to generate its first revenue this year,...
PAOG CBD Nutraceutical Launch Timed To Capture Market Momentum
Sandusky, OH, Sept. 29, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) has announced plans to soon launch a CBD nutraceuticals line of products expected to generate revenue this year, in 2021. Today the company highlights CBD industry...
PAOG CBD Nutraceutical Launch Timed To Capture Market Momentum
Sandusky, OH, Sept. 29, 2021 — McapMediaWire — PAO Group, Inc. (OTC Pink: PAOG) has announced plans to soon launch a CBD nutraceuticals line of products expected to generate revenue this year, in 2021.
Source: https://incomestatements.info
Category: Stock Reports